{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:59:24Z","timestamp":1793627964098,"version":"4.5.1"},"reference-count":26,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2021,4,30]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>To describe the clincopathological features and evaluate risk factors of post-transplant lymphoproliferative disorder (PTLD) after allogeneic haematopoietic stem cell transplants (allo-HSCT), with comparison between paediatric and adult .<\/jats:p>\n               <jats:p>Clinicopathological features of 81 cases of PTLD after allo-HSCT were analysed by histopatholgy, immunohistochemistry and in situ hybridisatioin.<\/jats:p>\n               <jats:p>The cases included 58 males and 23 females with a median age of 26.7 years (range 6\u201355 years) and the PTLDs developed 1\u201360 months post-transplant (mean 5.9 months). The histological types indicated 10 cases of non-destructive PTLD, including 4 of plasmacytic hyperplasia, 5 of infectious mononucleosis and 1 of florid follicular hyperplasia. Fifty-six cases were polymorphic PTLD, and 15 were monomorphic PTLD, including thirteen of diffuse large B cell lymphoma, 1 of extranodal nasal type natural killer (NK)\/T cell lymphoma and 1 of plasmablastic lymphoma. Foci and sheets of necrosis were observed in 31 cases. The infected ratio of Epstein-Barr virus (EBV) was 91.4%. Some cases were treated by reduction of immunosuppression, antiviral therapy, donor lymphocyte infusion or anti-CD20 monoclonal rituximab. Thirty-three cases died. Compared with that of adult, overall survival of paediatric recipient may be better.<\/jats:p>\n               <jats:p>The first half year after allo-HSCT is very important for the development of PTLD. Type of PTLD, EBV infection and graft-versus-host disease are risk factors. The prognosis of PTLD is poor, and PTLD after allo-HSCT exhibits some features different from that after solid organ transplantation and some differences existing between adult and paediatric recipients.<\/jats:p>","DOI":"10.1136\/jclinpath-2021-207492","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T13:26:44Z","timestamp":1621430804000},"page":"697-703","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult"],"prefix":"10.1136","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-3550","authenticated-orcid":false,"given":"Ding Bao","family":"Chen","sequence":"first","affiliation":[{"name":"Pathology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Pathology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang Zhou","family":"Kong","sequence":"additional","affiliation":[{"name":"Pathology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Hematology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Hua","family":"Shen","sequence":"additional","affiliation":[{"name":"Pathology, Peking University People's Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"2025092510193076000_74.11.697.1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"2025092510193076000_74.11.697.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2025092510193076000_74.11.697.3","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1786"},{"key":"2025092510193076000_74.11.697.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020328","article-title":"Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation: pathogenesis, risk factors and clinical outcomes","volume":"12","author":"Fujimoto","year":"2020","journal-title":"Cancers"},{"key":"2025092510193076000_74.11.697.5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025092510193076000_74.11.697.6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.13131","article-title":"Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation","volume":"101","author":"Ru","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025092510193076000_74.11.697.7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144428"},{"key":"2025092510193076000_74.11.697.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.035"},{"key":"2025092510193076000_74.11.697.9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq231"},{"key":"2025092510193076000_74.11.697.10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00325.x"},{"key":"2025092510193076000_74.11.697.11","first-page":"2208","article-title":"Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study","volume":"94","author":"Curtis","year":"1999","journal-title":"Blood"},{"key":"2025092510193076000_74.11.697.12","first-page":"996","article-title":"[A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation]","volume":"46","author":"Xu","year":"2007","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2025092510193076000_74.11.697.13","first-page":"955","article-title":"[The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation]","volume":"49","author":"Xu","year":"2010","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2025092510193076000_74.11.697.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213317.59176.d2"},{"key":"2025092510193076000_74.11.697.15","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13652"},{"key":"2025092510193076000_74.11.697.16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbmt.2018.02.026","article-title":"Epstein-Barr virus-related post-transplantation lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Liu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025092510193076000_74.11.697.17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood.V85.2.552.552","article-title":"Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders","volume":"85","author":"Knowles","year":"1995","journal-title":"Blood"},{"key":"2025092510193076000_74.11.697.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2007.02870.x"},{"key":"2025092510193076000_74.11.697.19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.039214"},{"key":"2025092510193076000_74.11.697.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(96)90369-X"},{"key":"2025092510193076000_74.11.697.21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.5858\/2007-131-1209-TCSOPL","article-title":"The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders","volume":"131","author":"Tsao","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"2025092510193076000_74.11.697.22","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0271"},{"key":"2025092510193076000_74.11.697.23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ejh.13230","article-title":"Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants","volume":"102","author":"Prem","year":"2019","journal-title":"Eur J Haematol"},{"key":"2025092510193076000_74.11.697.24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/TP.0b013e3181c69855","article-title":"Impact of HLA mismatching on incidence of posttransplant non-Hodgkin lymphoma after kidney transplantation","volume":"89","author":"Opelz","year":"2010","journal-title":"Transplantation"},{"key":"2025092510193076000_74.11.697.25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5500\/wjt.v10.i2.29","article-title":"Post-Transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches","volume":"10","author":"Abbas","year":"2020","journal-title":"World J Transplant"},{"key":"2025092510193076000_74.11.697.26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00430-019-00629-2","article-title":"Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study","volume":"208","author":"Chiereghin","year":"2019","journal-title":"Med Microbiol Immunol"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2021-207492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:19:39Z","timestamp":1758820779000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2021-207492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/jclinpath-2021-207492"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2021-207492","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}